<DOC>
	<DOC>NCT02213861</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy, safety and tolerability of SHAPE administered topically to skin lesions in patients with early-stage cutaneous T-cell lymphoma (CTCL).</brief_summary>
	<brief_title>Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma</brief_title>
	<detailed_description>This is a Phase 2, multicenter, open-label, randomized study to evaluate the efficacy and safety of SHAPE Gelled Solution applied topically daily or twice daily for 26 consecutive weeks to specified skin lesions in patients with Stage IA, IB or IIA CTCL. Patients responding to treatment will be allowed to continue on study for a maximum of 52 weeks.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
	<mesh_term>Histone Deacetylase Inhibitors</mesh_term>
	<criteria>Histological confirmation of CTCL; a documented verifiable biopsy report is required Documented clinical stage IA, IB or IIA CTCL Skin lesion involvement of at least 2% of BSA accessible for topical application of study drug ECOG performance status of 02 CTCL with histologic evidence of folliculotropic variant or large cell transformed CTCL Palpable lymph node â‰¥1.5 cm in diameter (unless the lymph node has been biopsied and designated as Stage IAIIA disease) Coexistent second malignancy or history of prior solid organ malignancy within previous 5 years (excluding basal or squamous cell carcinoma, in situ carcinoma of the cervix (CIN3), papillary or follicular thyroid cancer or prostate cancer that has been treated curatively Any prior history of hematologic malignancy (other than CTCL) within past 5 years CTCL disease that is known to be refractory to systemic histone deacetylase inhibitors Prior or concurrent central nervous system (CNS) metastases History of or current major gastrointestinal, pulmonary, cardiovascular, genitourinary or hematologic disease, CNS disorders, infectious disease or coagulation disorders as determined by the Investigator Evidence of active Hepatitis B or C or HIV Circulating atypical cells of clinical significance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>CTCL</keyword>
	<keyword>Cutaneous T-Cell Lymphoma</keyword>
	<keyword>Early-stage</keyword>
	<keyword>SHAPE</keyword>
	<keyword>SHP-141</keyword>
	<keyword>topical</keyword>
	<keyword>Histone deacetylase inhibitor</keyword>
	<keyword>CAILS</keyword>
	<keyword>mSWAT</keyword>
	<keyword>mycosis fungoides</keyword>
</DOC>